Parametric Portfolio Associates LLC lifted its holdings in Adaptive Biotechnologies Corporation (NASDAQ:ADPT) by 51.1% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 58,268 shares of the company’s stock after purchasing an additional 19,693 shares during the period. Parametric Portfolio Associates LLC’s holdings in Adaptive Biotechnologies were worth $1,619,000 as of its most recent filing with the Securities & Exchange Commission.
Several other institutional investors have also made changes to their positions in ADPT. BlackRock Inc. increased its stake in shares of Adaptive Biotechnologies by 57.1% in the 1st quarter. BlackRock Inc. now owns 4,960,832 shares of the company’s stock valued at $137,812,000 after purchasing an additional 1,802,283 shares in the last quarter. Frontier Capital Management Co. LLC boosted its holdings in Adaptive Biotechnologies by 188.3% in the 1st quarter. Frontier Capital Management Co. LLC now owns 946,710 shares of the company’s stock worth $26,300,000 after buying an additional 618,353 shares during the last quarter. Massachusetts Financial Services Co. MA boosted its holdings in Adaptive Biotechnologies by 99.9% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 1,071,945 shares of the company’s stock worth $32,072,000 after buying an additional 535,571 shares during the last quarter. State Street Corp boosted its holdings in Adaptive Biotechnologies by 174.7% in the 1st quarter. State Street Corp now owns 713,896 shares of the company’s stock worth $19,832,000 after buying an additional 454,043 shares during the last quarter. Finally, Man Group plc boosted its holdings in Adaptive Biotechnologies by 601.5% in the 4th quarter. Man Group plc now owns 430,809 shares of the company’s stock worth $12,889,000 after buying an additional 369,397 shares during the last quarter. Hedge funds and other institutional investors own 76.23% of the company’s stock.
Several equities research analysts recently issued reports on ADPT shares. Zacks Investment Research cut Adaptive Biotechnologies from a “buy” rating to a “hold” rating in a report on Monday, May 11th. BTIG Research restated a “buy” rating and set a $46.00 target price on shares of Adaptive Biotechnologies in a report on Friday, April 17th. ValuEngine upgraded Adaptive Biotechnologies from a “hold” rating to a “buy” rating in a report on Thursday, April 2nd. Guggenheim boosted their target price on Adaptive Biotechnologies from $44.00 to $50.00 and gave the stock a “buy” rating in a report on Tuesday, May 19th. Finally, Goldman Sachs Group initiated coverage on Adaptive Biotechnologies in a report on Wednesday, June 3rd. They set a “buy” rating and a $60.00 target price on the stock. One research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. Adaptive Biotechnologies has a consensus rating of “Buy” and an average price target of $47.67.
Adaptive Biotechnologies (NASDAQ:ADPT) last released its quarterly earnings data on Tuesday, May 12th. The company reported ($0.25) EPS for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.04). Adaptive Biotechnologies had a negative net margin of 87.47% and a negative return on equity of 22.92%. The business had revenue of $20.91 million during the quarter, compared to analyst estimates of $21.52 million. The company’s revenue was up 65.1% compared to the same quarter last year. As a group, equities analysts predict that Adaptive Biotechnologies Corporation will post -1.05 earnings per share for the current year.
In other Adaptive Biotechnologies news, insider Harlan S. Robins sold 11,100 shares of the business’s stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $46.88, for a total value of $520,368.00. Following the sale, the insider now owns 11,779 shares of the company’s stock, valued at $552,199.52. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP Stacy L. Taylor sold 19,580 shares of the business’s stock in a transaction that occurred on Monday, April 27th. The shares were sold at an average price of $30.22, for a total value of $591,707.60. Following the completion of the sale, the senior vice president now directly owns 9,610 shares in the company, valued at approximately $290,414.20. The disclosure for this sale can be found here. Insiders sold 646,140 shares of company stock worth $24,165,127 over the last quarter. 22.20% of the stock is currently owned by insiders.
Adaptive Biotechnologies Company Profile
Adaptive Biotechnologies Corporation develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ research service and kit that is used to answer research questions that inform current and future clinical trials, as well as to discover new prognostic and diagnostic signals.
Read More: Guidelines for Successful Channel Trading
Receive News & Ratings for Adaptive Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptive Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.